CP 316311

Drug Profile

CP 316311

Alternative Names: Corticotropin releasing factor antagonist - Pfizer; Corticotropin releasing hormone antagonist - Pfizer

Latest Information Update: 23 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antidepressants
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 23 Aug 2006 Discontinued - Phase-II for Anxiety disorders in USA (unspecified route)
  • 23 Aug 2006 Discontinued - Phase-II for Depression in USA (unspecified route)
  • 05 Jan 2005 Phase-II clinical trials in Anxiety disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top